Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials

Tumor sidedness and hyperselection status significantly influence maintenance strategy efficacy in mCRC. For left-sided, negative hyperselected patients, Panitumumab monotherapy may optimize efficacy while minimizing toxicity. Further investigation into the relative contribution of individual hyperselection parameters in this setting is warranted.

Authors

Institutions

Publication Details

Journal
British Journal of Cancer
Published
2025-08-28
DOI
https://doi.org/10.1038/s41416-025-03164-5
Citations
3
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
3.14
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials

Arndt Stahler, Alessandra Raimondi, Armin Jarosch, Sebastian Stintzing et al.
3 citations
British Journal of Cancer
Colorectal Cancer Treatments and Studies
3.14
article

Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials

Arndt Stahler, Alessandra Raimondi, Armin Jarosch, Sebastian Stintzing, Annika Kurreck, Alexej Ballhausen, Andreas Jay Kind, Michele Prisciandaro, Sara Lonardi, Dominik Paul Modest, Annabel Helga Sophie Alig, Federica Morano, Giovanni Randon, David Horst, Chiara Pircher, Filippo Pietrantonio, Chiara Cremolini, Anna Chiaramonte, Paola Andena, Susanna Swoboda
article en
3 citations

Abstract

Tumor sidedness and hyperselection status significantly influence maintenance strategy efficacy in mCRC. For left-sided, negative hyperselected patients, Panitumumab monotherapy may optimize efficacy while minimizing toxicity. Further investigation into the relative contribution of individual hyperselection parameters in this setting is warranted.

British Journal of CancerVol. 133(9)
University of Pisa (IT), German Cancer Research Center (DE), Heidelberg University (DE), Humboldt-Universität zu Berlin (DE), Istituto Oncologico Veneto (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Universitaria Pisana (IT)
Openalex Percentile: Top 7%
Colorectal Cancer Treatments and Studies
3.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.